alogliptin Side Effects
Also known as: Nesina
Analysis of 3,393 adverse event reports submitted to the FDA from 2011 to 2025.
Total Reports
3,393
Death-Related
356
10.5% of reports
Hospitalizations
1,564
46.1% of reports
Top Indication
Type 2 Diabetes Mellitus
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 356 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 71 |
| DIARRHOEA | 19 |
| PNEUMONIA | 19 |
| MALIGNANT NEOPLASM PROGRESSION | 18 |
| PYREXIA | 16 |
| INTERSTITIAL LUNG DISEASE | 15 |
| DECREASED APPETITE | 14 |
| CONDITION AGGRAVATED | 13 |
| SUDDEN DEATH | 13 |
| CARDIAC FAILURE | 12 |
| DISSEMINATED INTRAVASCULAR COAGULATION | 12 |
| PEMPHIGOID | 12 |
| VOMITING | 12 |
| CEREBRAL INFARCTION | 11 |
| SEPSIS | 11 |
| DEHYDRATION | 10 |
| PULMONARY ARTERIAL HYPERTENSION | 10 |
| MYOCARDIAL INFARCTION | 9 |
| NAUSEA | 9 |
| PLATELET COUNT DECREASED | 9 |
Reactions in Hospitalization Reports
Top reactions in 1,564 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ACUTE KIDNEY INJURY | 75 |
| PYREXIA | 62 |
| PNEUMONIA | 60 |
| VOMITING | 58 |
| DIARRHOEA | 57 |
| INTERSTITIAL LUNG DISEASE | 53 |
| DECREASED APPETITE | 51 |
| CEREBRAL INFARCTION | 48 |
| HYPOGLYCAEMIA | 46 |
| NAUSEA | 44 |
| FALL | 43 |
| BLOOD GLUCOSE INCREASED | 41 |
| CONDITION AGGRAVATED | 41 |
| DIABETIC KETOACIDOSIS | 41 |
| LACTIC ACIDOSIS | 40 |
| PEMPHIGOID | 40 |
| MALAISE | 39 |
| CONSTIPATION | 38 |
| PANCREATITIS ACUTE | 38 |
| RASH | 36 |
Nearby — Related Medications
What the FAERS Data Reveals About alogliptin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 3,393 voluntary reports linked to alogliptin and its brand equivalents (Nesina), spanning 2011 through 2025. Of those, 356 (10.5%) listed death as an outcome and 1,564 (46.1%) involved hospitalization. The most common indication reported alongside adverse events was Type 2 Diabetes Mellitus.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 42% were female and 58% male; age distribution skews toward 75+, with 885 reports in that bracket. The single most reported reaction is diarrhoea with 134 submissions, followed by nausea and vomiting.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.